Nouscom new Science Translational Medicine publication is highlighted on Cancer Discovery #ResearchWatch, describing a novel mechanism of action driven by viral vector-based vaccine platform [...]
Nouscom recently published in the Journal for ImmunoTherapy of Cancer a manuscript entitled: “Maximizing cancer therapy via complementary mechanisms of immune activation: PD-1 blockade, [...]
VENUS (Vaccine-Encoded Neoantigens Unrestricted Selection) is Nouscom’s proprietary algorithm designed to enhance the predictive accuracy of personalized neoantigen selections that may induce an [...]
Oncolytic viruses (OVs) are novel anti-tumor agents with the ability to selectively infect and kill tumor cells while sparing normal tissue. Beyond tumor cytolysis, OVs are capable of priming an [...]
ABSTRACT – Since the discovery in 1796 by Edward Jenner of vaccinia virus as a way to prevent and finally eradicate smallpox, the concept of using a virus to fight another virus has evolved [...]
22th July 2020 – Article entitled ‘A genetic vaccine encoding shared cancer neoantigens to treat tumors with Microsatellite Instability’ published in Cancer Research Nouscom, an [...]
19th June 2019 – Article published in Nature Communications Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today the [...]
ABSTRACT IMPORTANCE Colorectal carcinomas in patients with Lynch syndrome (LS) arise in a background of mismatch repair (MMR) deficiency, display a unique immune profile with upregulation of [...]
Nouscom is a private oncology company developing next generation immunotherapies, founded in 2015 by an experienced management team that has worked together for many years in previous successful enterprises. Nouscom’s proprietary technology platform harnesses the full power of the immune response by combining viral vectored genetic vaccines based on neoantigens with other immunomodulators.
